383 related articles for article (PubMed ID: 6229580)
21. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
Pangburn MK; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
[TBL] [Abstract][Full Text] [Related]
22. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
Gigli I; Fujita T; Nussenzweig V
Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
[TBL] [Abstract][Full Text] [Related]
23. Regulation of the alternative pathway of human complement by C1q.
Fishelson Z; Müller-Eberhard HJ
Mol Immunol; 1987 Sep; 24(9):987-93. PubMed ID: 2958692
[TBL] [Abstract][Full Text] [Related]
24. Isolation and characterization of a 33,000-dalton fragment of complement Factor B with catalytic and C3b binding activity.
Lambris JD; Müller-Eberhard HJ
J Biol Chem; 1984 Oct; 259(20):12685-90. PubMed ID: 6567645
[TBL] [Abstract][Full Text] [Related]
25. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
[TBL] [Abstract][Full Text] [Related]
26. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
Sahu A; Isaacs SN; Soulika AM; Lambris JD
J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
[TBL] [Abstract][Full Text] [Related]
27. Reconstitution of C5 convertase of the alternative complement pathway with isolated C3b dimer and factors B and D.
Hong K; Kinoshita T; Pramoonjago P; Kim YU; Seya T; Inoue K
J Immunol; 1991 Mar; 146(6):1868-73. PubMed ID: 2005382
[TBL] [Abstract][Full Text] [Related]
28. Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor.
Daha MR; Kok DJ; Van Es LA
Clin Exp Immunol; 1982 Oct; 50(1):209-14. PubMed ID: 6216999
[TBL] [Abstract][Full Text] [Related]
29. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.
Parker CJ; Baker PJ; Rosse WF
J Clin Invest; 1982 Feb; 69(2):337-46. PubMed ID: 6915939
[TBL] [Abstract][Full Text] [Related]
30. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP).
Seya T; Okada M; Matsumoto M; Hong KS; Kinoshita T; Atkinson JP
Mol Immunol; 1991 Oct; 28(10):1137-47. PubMed ID: 1833639
[TBL] [Abstract][Full Text] [Related]
31. Site-specific activation of the alternative pathway of complement. Synthesis of a hybrid molecule consisting of antibody and cobra venom factor.
Parker CJ; White VF; Falk RJ
Complement; 1986; 3(4):223-35. PubMed ID: 3643079
[TBL] [Abstract][Full Text] [Related]
32. The activation of the C3b feedback cycle with human complement components. II. Using components of the alternative pathway.
Mak LW; Majewski J; Lachmann PJ
Clin Exp Immunol; 1977 Nov; 30(2):211-21. PubMed ID: 606443
[TBL] [Abstract][Full Text] [Related]
33. Reduced activity of DAF on complement enzymes bound to alternative pathway activators. Similarity with Factor H.
Pangburn MK
Immunology; 1990 Dec; 71(4):598-600. PubMed ID: 1703989
[TBL] [Abstract][Full Text] [Related]
34. Characterization of the initial C3 convertase of the alternative pathway of human complement.
Fishelson Z; Pangburn MK; Müller-Eberhard HJ
J Immunol; 1984 Mar; 132(3):1430-4. PubMed ID: 6559201
[TBL] [Abstract][Full Text] [Related]
35. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
[TBL] [Abstract][Full Text] [Related]
36. Functional role of the noncatalytic subunit of complement C5 convertase.
Rawal N; Pangburn MK
J Immunol; 2000 Feb; 164(3):1379-85. PubMed ID: 10640753
[TBL] [Abstract][Full Text] [Related]
37. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
Hew BE; Pangburn MK; Vogel CW; Fritzinger DC
Toxicon; 2020 Sep; 184():68-77. PubMed ID: 32526239
[TBL] [Abstract][Full Text] [Related]
38. The inhibitory effect of factor J on the alternative complement pathway.
González-Rubio C; Jiménez-Clavero MA; Fontán G; López-Trascasa M
J Biol Chem; 1994 Oct; 269(42):26017-24. PubMed ID: 7929312
[TBL] [Abstract][Full Text] [Related]
39. The low C5 convertase activity of the C4A6 allotype of human complement component C4.
Kinoshita T; Dodds AW; Law SK; Inoue K
Biochem J; 1989 Aug; 261(3):743-8. PubMed ID: 2803239
[TBL] [Abstract][Full Text] [Related]
40. Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.
Jelezarova E; Vogt A; Lutz HU
Biochem J; 2000 Jul; 349(Pt 1):217-23. PubMed ID: 10861231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
